CJC-1295 With DAC is a long-acting GHRH analog with albumin-binding modification that sustains elevated GH and IGF-1 for 6–8 days per administration in preclinical and early clinical research.
Product definition
What is CJC-1295 With DAC?
CJC-1295 With DAC is a long-acting GHRH analog with albumin-binding modification that sustains elevated GH and IGF-1 for 6–8 days per administration in preclinical and early clinical research.
CJC-1295 With DAC (also known as DAC:GRF) is a synthetic GHRH analog with a maleimide-modified lysine residue that forms a covalent bond with serum albumin following administration. This albumin-binding mechanism — the Drug Affinity Complex (DAC) technology — dramatically extends plasma half-life and produces a sustained pulsatile GH secretion pattern over approximately one week per dose.
The compound was investigated in Phase I/II clinical studies by ConjuChem Inc., where it demonstrated dose-dependent GH and IGF-1 elevation with a half-life of approximately 6–8 days in human volunteers. The research profile documents its utility in sustained GH axis stimulation, with potential applications in body composition research, metabolic studies, and investigations of GH-dependent anabolic signaling pathways.
Research context
How is CJC-1295 With DAC described in the research literature?
CJC-1295 With DAC stimulates GH secretion by binding and activating GHRH receptors on pituitary somatotropes. The Drug Affinity Complex (DAC) modification enables covalent albumin binding in vivo, extending the half-life from minutes (native GHRH) to approximately 6–8 days. Preclinical and Phase I human data show dose-dependent GH and IGF-1 elevation following single administration.
Compound profile
Key facts about CJC-1295 With DAC
- Class
- Long-acting GHRH analog
- Mechanism
- GHRH receptor agonist with albumin binding
- Molecular weight
- ~3,367 Da
- Half-life
- ~6–8 days (albumin-bound in vivo)
- CAS
- 863288-34-0
- Research category
- Growth hormone axis, GH secretagogue, anabolic signaling
- Clinical research
- Phase I/II human pharmacokinetic data published
- Storage
- Lyophilized: −20°C. Reconstituted: 2–8°C, use within 30 days
Research areas
What research areas is CJC-1295 With DAC associated with?
- Studied in Phase I human research for sustained GH secretion lasting 6–8 days per administration
- Dose-dependent GH AUC increases of 2–10-fold documented in early-phase clinical pharmacokinetic data
- Albumin-binding DAC modification extends half-life from minutes (native GHRH) to approximately one week
- Investigated for IGF-1 elevation and downstream anabolic signaling in GH-axis research
- Most pharmacokinetically characterized long-acting GHRH analog in published literature
- Research protocols benefit from reduced administration frequency vs. short-acting GHRH analogs
Research audience
Who researches CJC-1295 With DAC?
CJC-1295 With DAC is used by researchers studying the growth hormone axis, GHRH receptor pharmacology, sustained GH secretion protocols, GH-dependent metabolic signaling, and body composition mechanisms. It is particularly valuable in protocols requiring sustained GH elevation without frequent compound administration.
Preclinical research overview
What does the preclinical literature say about CJC-1295 With DAC?
CJC-1295 With DAC was developed by ConjuChem using their Drug Affinity Complex technology, which was designed to extend the half-life of peptide therapeutics through in-vivo albumin binding. The compound was taken through Phase I and early Phase II human trials before development was discontinued for commercial reasons unrelated to safety or efficacy signals.
The published pharmacokinetic data from these studies represents the most rigorous human-subject characterization of a long-acting GHRH analog in the open literature. Dose-dependent GH and IGF-1 responses were confirmed across multiple dose cohorts, with a mean half-life of 6–8 days and GH AUC increases ranging from approximately 2-fold at low doses to 10-fold at higher doses.
In preclinical research, CJC-1295 With DAC has been studied in contexts including muscle mass preservation, GH-dependent metabolic effects, and GH axis modulation in aging models. The compound remains a reference standard in GH secretagogue research due to the availability of published pharmacokinetic data.
Common questions
Frequently asked about CJC-1295 With DAC
What is the difference between CJC-1295 With DAC and Without DAC?
CJC-1295 With DAC has the maleimide-lysine modification that enables albumin binding and a ~6–8 day half-life. CJC-1295 Without DAC (also called MOD GRF 1-29) lacks this modification and has a half-life of approximately 30 minutes. With DAC produces a sustained, blunted GH elevation; Without DAC produces a sharp pulsatile GH release closer to the physiological pattern.
Has CJC-1295 With DAC been studied in humans?
Yes. ConjuChem conducted Phase I and early Phase II clinical trials with CJC-1295 With DAC in human volunteers, producing published pharmacokinetic and pharmacodynamic data. This human-subject data is available in the published literature and is one of the distinguishing features of this compound's research profile compared to many other GHRH analogs.
What is the GH secretion pattern produced by CJC-1295 With DAC?
The albumin-binding mechanism produces a sustained, gradual elevation in baseline GH and IGF-1 rather than the sharp pulsatile spikes associated with short-acting GHRH analogs. Researchers studying chronic GH axis stimulation or GH-dependent downstream signaling over extended observation windows use CJC-1295 With DAC specifically for this sustained profile.
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy